Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
To the editor: In a recent editorial in Molecular Therapy, Büning and Schmidt1Büning H Schmidt M Adeno-associated vector toxicity—to be or not to be?.Mol Ther. 2015; 23: 1673-1675Abstract Full Text Full Text PDF PubMed Scopus (53) Google Scholar discussed the role of gene therapy vectors based on adeno-associated viruses (AAVs) in the development of liver tumors following the identification by Nault et al.2Nault J-C Datta S Imbeaud S Franconi A Mallet M Couchy G et al.Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas.Nat Genet. 2015; 47: 1187-1193Crossref PubMed Scopus (312) Google Scholar of recurrent AAV2 clonal insertions in 11 cases of hepatocellular carcinoma (HCC). In this editorial, the authors appear to confound the issue of AAV2 insertion in HCC development with the risk of AAV2-based vector genotoxicity. Here, we aim to clarify our interpretation of the occurrence of AAV2 insertions in spontaneous human HCC, which are clearly unrelated to vectorized AAV used in gene therapy. Büning and Schmidt asked whether AAV2 insertions observed in human HCC could be passenger or cancer driver events. By analyzing 193 specimens of HCC, we identified clonal AAV2 insertions, all occurring in genes (TERT, CCNE1, KMT2B, TNFSF10, and CCNA2) known to be involved in cancer development. Moreover, each of these insertions was associated with overexpression of the corresponding targeted gene. These results showed that the AAV2 insertions are recurrent clonal genomic alterations selected during the natural history of HCC development. In agreement with the general multistep molecular mechanism observed in solid tumor development, other mutations accumulated in additional cancer driver genes. In addition, we showed by functional analyses that AAV2 insertions in either the TERT promoter or the TNFSF10 3°-UTR increased the promoter activity and luciferase expression in cellulo. All of these results showed that AAV2 insertion met the criteria of a cancer driver event selected during tumor development in humans as defined by molecular oncologists.3Alizadeh AA Aranda V Bardelli A Blanpain C Bock C Borowski C et al.Toward understanding and exploiting tumor heterogeneity.Nat Med. 2015; 21: 846-853Crossref PubMed Scopus (451) Google Scholar The authors suggested that the small size of the inserted viral sequences and the occurrence of these insertions in either intronic or exonic coding or noncoding human sequences argued against a genotoxic effect of AAV2. However, similar viral oncogenic insertions have been identified in HCC involving small parts of the hepatitis B virus (HBV) genome. Both viruses have the ability to insert into the hepatocyte genome and to induce insertional mutagenesis distributed over the human genome, introducing enhancer or promoter sequences; they could also stabilize targeted messenger RNA or disrupt coding sequences. Interestingly, recurrent insertions of AAV2 and HBV target the same loci in the promoters of the telomerase (TERT), cyclins (CCNA2 and CCNE1) and MLL4 genes.4Paterlini-Brechot P Saigo K Murakami Y Chami M Gozuacik D Mugnier C et al.Hepatitis B virus–related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene.Oncogene. 2003; 22: 3911-3916Crossref PubMed Scopus (267) Google Scholar,5Sung WK Zheng H Li S Chen R Liu X Li Y et al.Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma.Nat Genet. 2012; 44: 765-769Crossref PubMed Scopus (638) Google Scholar Clonal AAV2 insertion in human HCC is a very rare event, and oncogenic insertional mutagenesis by the latter is significantly less frequent than that induced by insertions of HBV, taking into account the large fraction of the population who are infected by AAV2 during their lifetime. Büning and Schmidt were surprised by the lack of recurrent AAV2 insertions observed at the AAVS1 region, a 4-kilobase locus at chromosome 19q13.42 previously described as a hot spot for AAV insertions.6Samulski RJ Zhu X Xiao X Brook JD Housman DE Epstein N et al.Targeted integration of adeno-associated virus (AAV) into human chromosome 19.EMBO J. 1991; 10: 3941-3950Crossref PubMed Scopus (664) Google Scholar However, recurrent insertions at AAVS1 were identified in cell culture and mainly in HeLa cells, a highly proliferative cervical carcinoma–derived cell line presenting HPV insertions and a large number of chromosome rearrangements, including chromothripsis at chromosome 19. Moreover, this hot spot of insertion was identified using PCR-based techniques, whereas we used a DNA capture strategy unbiased by DNA amplification to isolate AAV2 insertions in liver tissues. In 27 human liver tissues, clonal and nonclonal AAV2 insertion events were distributed all over the human genome without clustering within AAVS1. This is the result of the natural history of AAV2 infection in vivo in adult human hepatocytes. Altogether, these results suggest that artificial in
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AAV vector integration sites in mouse hepatocellular carcinoma
Donsante, A., Miller, D. G., Li, Y., Vogler, C., Brunt, E. M., Russell, D. W., & Sands, M. S. (2007) · Science · doi:10.1126/science.1142658 · Cited by 662
Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas
Nault, J.-C., Datta, S., Imbeaud, S., Franconi, A., Mallet, M., Couchy, G., Letouzé, E., Pilati, C., Verret, B., Blanc, J.-F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3389 · Cited by 489
Self-citationVector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S., Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun, A. G., Burgess, S. M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79213 · Cited by 403
Cited by
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
In vivo base editing rescues Hutchinson–Gilford progeria syndrome in mice
Koblan, L. W., Erdos, M. R., Wilson, C., Cabral, W. A., Levy, J. M., Xiong, Z.-M., Tavarez, U. L., Davison, L. M., Gete, Y. G., Mao, X., et al. (2021) · Nature · doi:10.1038/s41586-020-03086-7 · Cited by 483
Konkle, B. A., Walsh, C. E., Escobar, M. A., Josephson, N. C., Young, G., von Drygalski, A., McPhee, S. W. J., Samulski, R. J., Bilic, I., de la Rosa, M., et al. (2021) · Blood · doi:10.1182/blood.2019004625 · Cited by 189
Ertl, H. C. J., & High, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.172 · Cited by 94
“A recent report that linked AAV to hepatocellular carcinoma 28 was dismissed by experts in the field, 29,30 and according to the authors was not meant to establish a link between rAAV gene transfer and increased risk of liver cancer.”
Humoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
Metadata
- Authors
- Nault, J.-C., Mami, I., La Bella, T., Datta, S., Imbeaud, S., Franconi, A., Mallet, M., Couchy, G., Letouzé, E., Pilati, C., Verret, B., Blanc, J.-F., Balabaud, C., Calderaro, J., Laurent, A., Letexier, M., Bioulac-Sage, P., Calvo, F., & Zucman-Rossi, J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 24
- Issue
- 4
- Pages
- 660-661
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2340278309
- Cited by
- 39
- References
- 3
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV. https://app.cochat.ai/papers/10.1038/mt.2016.47
- The paper
- Nault, J.-C., Mami, I., La Bella, T., Datta, S., Imbeaud, S., Franconi, A., Mallet, M., Couchy, G., Letouzé, E., Pilati, C., Verret, B., Blanc, J.-F., Balabaud, C., Calderaro, J., Laurent, A., Letexier, M., Bioulac-Sage, P., Calvo, F., & Zucman-Rossi, J. (2016). Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV. Molecular Therapy. https://doi.org/10.1038/mt.2016.47
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.